Mesa Laboratories Inc (MLAB) FinancialsMLABMesa Laboratories Inc

Mesa Laboratories, Inc. (MLAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Discrete Revenues- Consumables, accounting for 62.9% of total sales, equivalent to $40.06M. Other significant revenue streams include Discrete Revenues- Hardware and Software and Contracted Revenues- Services. Understanding this composition is critical for investors evaluating how MLAB navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Mesa Laboratories, Inc. maintains a gross margin of 64.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.69%, while the net margin is 4.71%. These profitability ratios, combined with a Return on Equity (ROE) of 2.66%, provide a clear picture of how effectively MLAB converts its operational activities into shareholder value.

In the context of the broader market, MLAB competes directly with industry leaders such as CTKB and PACB. With a market capitalization of $705.97M, it holds a significant position in the sector. When comparing efficiency, MLAB's gross margin of 64.87% stands against CTKB's 58.87% and PACB's 30.26%. Such benchmarking helps identify whether Mesa Laboratories, Inc. is trading at a premium or discount relative to its financial performance.

Mesa Laboratories has shown fluctuating net income, with a recent net income of $2.83 million for Q1 2027, but also reported a net loss of $4.14 million in Q4 2026. The gross margin has improved to 64.87%, indicating better cost management, but the inconsistent earnings raise concerns.